NCT05155072

Brief Summary

A Randomized, Open-label, Oral in healthy male volunteers

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started May 2020

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 7, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 7, 2020

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

October 28, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 13, 2021

Completed
Last Updated

December 13, 2021

Status Verified

October 1, 2021

Enrollment Period

4 months

First QC Date

October 28, 2021

Last Update Submit

December 10, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • pH monitoring

    Pharmacodynamic Endpoint

    up to day 5

Study Arms (6)

Sequence A

EXPERIMENTAL
Drug: DW1903Drug: DW1903-R1Drug: DW1903-R2

Sequence B

EXPERIMENTAL
Drug: DW1903Drug: DW1903-R1Drug: DW1903-R2

Sequence C

EXPERIMENTAL
Drug: DW1903Drug: DW1903-R1Drug: DW1903-R2

Sequence D

EXPERIMENTAL
Drug: DW1903Drug: DW1903-R1Drug: DW1903-R2

Sequence E

EXPERIMENTAL
Drug: DW1903Drug: DW1903-R1Drug: DW1903-R2

Sequence F

EXPERIMENTAL
Drug: DW1903Drug: DW1903-R1Drug: DW1903-R2

Interventions

DW1903DRUG

DW1903

Sequence ASequence BSequence CSequence DSequence ESequence F

DW1903-R1

Sequence ASequence BSequence CSequence DSequence ESequence F

DW1903-R2

Sequence ASequence BSequence CSequence DSequence ESequence F

Eligibility Criteria

Age19 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy Volunteers who are ≥19 years old
  • BMI between 18 and 30 kg/m2
  • Body weight ≥50kg

You may not qualify if:

  • Clinically significant Medical History

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chungbuk National University Hospital

Cheongju-si, South Korea

Location

MeSH Terms

Conditions

Gastritis

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesDigestive System DiseasesStomach Diseases

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 28, 2021

First Posted

December 13, 2021

Study Start

May 15, 2020

Primary Completion

September 7, 2020

Study Completion

September 7, 2020

Last Updated

December 13, 2021

Record last verified: 2021-10

Locations